智擎生技製藥股份有限公司

  • About Us
    • Company Profile
    • Management Team
    • Business Model
    • Milestones
    • Contact Us
  • Product & Pipeline
    • ONIVYDE®
    • PEP07 (CHK1 inhibitor)
    • PEP08 (PRMT5:MTA inhibitor)
  • Investors
    • Fundamentals
    • Events & Presentations
    • Financial Reports
    • Shareholders' Meeting
    • News
  • Corporate Governance
    • Overview
    • Board of Directors
    • Functional Committees
    • Communication with Independent Directors
    • Major Internal Policies
    • Risk Management
    • Cyber Security
    • Intellectual Property Management
  • Sustainability
    • Corporate Social Responsibility
    • Ethical Management
    • Stakeholder Communication
    • Human Rights
    • Health & Safety
  • Careers
  • EN
    • Chinese
  • Home
  • About Us
    • Company Profile
    • Management Team
    • Business Model
    • Milestones
    • Contact Us
  • Product & Pipeline
    • ONIVYDE®
    • PEP07 (CHK1 inhibitor)
    • PEP08 (PRMT5:MTA inhibitor)
  • Investors
    • Fundamentals
    • Events & Presentations
    • Financial Reports
    • Shareholders' Meeting
    • News
  • Corporate Governance
    • Overview
    • Board of Directors
    • Functional Committees
    • Communication with Independent Directors
    • Major Internal Policies
    • Risk Management
    • Cyber Security
    • Intellectual Property Management
  • Sustainability
    • Corporate Social Responsibility
    • Ethical Management
    • Stakeholder Communication
    • Human Rights
    • Health & Safety
  • Careers
  • Language
    • EN
    • Chinese

Fundamentals

  • Homepage
  • Investors
  • Fundamentals
  • Latest News

    • 2025-04-28

      PharmaEngine to present three posters in AACR 2025

    • 2025-02-05

      PharmaEngine to receive US$50 million in milestone payment as ONIVYDE's 2024 sales in Europe and Asia had reached second milestone

    • 2024-11-04

      PharmaEngine and Haihe Biopharma enter into exclusive distribution agreement for LIPORAXEL®

    More

    Events & Presentations

    More

    Financial Results

    More
    • About Us
    • Product & Pipeline
    • Investors
    • Corporate Governance
    • Sustainability
    • Careers
    • Contact Us
    • Privacy Policy
    • Terms of Use
    © 2023 智擎生技製藥股份有限公司 ALL RIGHTS RESERVED.
    Designed by JDDT